Frank Gentile

Tekla Capital Management LLC is an independent, SEC-registered investment advisor headquartered in Boston, Massachusetts. Formerly known as Hambrecht & Quist Capital Management LLC, the firm serves as an investment adviser for four closed-end funds – Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund.

CardioKinetix, Inc. develops ventricular partitioning device for heart failure disease. It develops transcatheter implant called the Parachute Ventricular Partitioning Device, which intends to treat heart failure resulting from a heart attack in patients by improving overall cardiac function. The company was founded by Alexander Khairkhahan, Serjan D. Nikolic and Hugh R. Sharkey in 2002 and is headquartered in Menlo Park, CA.

Conor Medsystems LLC develops vascular drug delivery technologies. Its products include controlled vascular drug delivery technologies and novel stent that are used in the treatment of coronary artery disease and delivery of a broad spectrum of therapeutic agents. The company was founded by John F. Shanley in 1999 and is headquartered in Menlo Park, CA.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Reprogenesis, Inc., located in Cambridge, Massachusetts developes tissue engineered therapies to treat unmet medical needs. The Company has proprietary technology utilizing the combination of cells and biomaterials to restore, repair or replace lost tissue or physiological function. The Company has a broad preclinical and clinical pipeline of products in the areas of urology, cardiovascular biology and plastic and reconstructive surgery. ChondrogelTM is its most advanced product

FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA.

Raven Biotechnologies, Inc. engages in the development of antibody therapeutics for the treatment for cancer, autoimmune disorders and infectious diseases. Its products are used in treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is headquartered in South San Francisco, CA.